Clinical Trial Update: Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial update notes the completed study on predictors for safely discontinuing anti-TNF therapy in Juvenile Idiopathic Arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Juvenile Idiopathic Arthritis | Phase 4 | Status: COMPLETED